Lantus, Insulin Glargine Newswire

Lantus, Insulin Glargine Newswire

Comprehensive Real-Time News Feed for Lantus, Insulin Glargine (generic).

Results 1 - 20 of 233 in Lantus, Insulin Glargine (generic)

  1. Sanofi Inks Deal to Swap Business with Boehringer IngelheimRead the original story

    Sunday Jun 26 | BioSpace

    June 27, 2016 By Mark Terry , BioSpace.com Breaking News Staff The paperwork has been signed between Paris-based Sanofi and Germany-based Boehringer Ingelheim , exchanging Sanofi's Merial animal drugs business with Boehringer's over-the-counter drugs business. The two companies began negotiations for the deal in December 2015 and is expected to close by the end of this year.

    Comment?

  2. Veterinarians: Excess weight often responsible for dog, cat diabetesRead the original story w/Photo

    Friday Jun 24 | Northern Virginia Daily

    Diabetes in dogs and cats occurs with regularity and may be more preventable than some think, according to area veterinarians. The condition is especially preventable in cats, said Dr. Gail Hartman, of Cedarville Veterinary Clinic in Front Royal.

    Comment?

  3. VIDEOThis Week in Managed Care: June 18, 2016Read the original story w/Photo

    Saturday Jun 18 | The American Journal of Managed Care

    This week, the top stories in managed care included study results presented at the 76th Scientific Sessions of the American Diabetes Association from the SWITCH and LEADER trials, a recommendation for a smarter way to screen for prostate cancer, and researchers found physicians underutilize medications to treat opioid addiction. Hello, I'm Cate Douglass with The American Journal of Managed Care .

    Comment?

  4. Merck's Lantus Biosimilar Queued for an FDA Submission?Read the original story w/Photo

    Thursday Jun 16 | JD Supra

    Merck, known as MSD outside the United States and Canada, announced promising results from two Phase III studies evaluating MK-1293 Merck's biosimilar to Lantus . Lantus is used for the treatment of people with type 1 and type 2 diabetes.

    Comment?

  5. FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults With Type 2 DiabetesRead the original story w/Photo

    May 24, 2016 | Drugs.com

    Sanofi announced today that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of the New Drug Application for the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide for the treatment of adults with type 2 diabetes. The 15-member panel voted 12 to 2 to approve the fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide.

    Comment?

  6. Semaglutide significantly reduces the risk of major adverse...Read the original story w/Photo

    Apr 27, 2016 | Drugs.com

    Novo Nordisk today announced the top-line results from the sixth and last global phase 3a trial, SUSTAIN6, for semaglutide; a new GLP-1 analogue, which is administered subcutaneously once weekly in the SUSTAIN trials. This double-blinded trial investigated the long-term cardiovascular and other safety outcomes of 0.5 mg and 1.0 mg semaglutide compared with placebo, both in addition to standard-of-care.

    Comment?

  7. Merck's insulin glargine biosimilar candidate matches Lantus in two late-stage studiesRead the original story w/Photo

    Monday Jun 13 | Seeking Alpha

    Two Phase 3 clinical trials to determine the non-inferiority of Merck's insulin glargine biosimilar candidate to Sanofi's Lantus 100 Units/mL, MK-1293, were successful. The results were presented at the 76th Scientific Sessions of the American Diabetes Association.

    Comment?

  8. Merck's Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies,...Read the original story w/Photo

    Monday Jun 13 | Freshnews

    Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76 th Scientific Sessions of the American Diabetes Association Merck's Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to Lantus A Merck , known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Merck's investigational, follow-on biologic* insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes.

    Comment?

  9. Sanofi Says LixiLan Diabetes Drug Trials Meet TargetsRead the original story w/Photo

    Monday Jun 13 | Medical Daily

    LixiLan consists of a single-injection combination of Lyxumia, a drug developed with Danish drugmaker Zealand Pharma, and Sanofi's Lantus. It targets patients suffering from type 2 diabetes.

    Comment?

  10. Merck & Co.??'s Investigational Insulin Glargine, MK-1293, Met...Read the original story

    Sunday Jun 12 | BioSpace

    Merck , known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Merck's investigational, follow-on biologic* insulin glargine candidate for the treatment of people with type 1 and type 2 diabetes. In both studies, MK-1293 achieved its primary endpoint by demonstrating non-inferiority in change from baseline A1C and similar safety to LantusA ** after 24 weeks in patients with type 1 and type 2 diabetes.

    Comment?

  11. Novo Nordisk A/S Release: Tresiba (Insulin Degludec Injection U-100)...Read the original story

    Sunday Jun 12 | BioSpace

    Novo Nordisk A/S Release: Tresiba Demonstrated Significantly Lower Rates Of Overall, Nocturnal And Severe Hypoglycaemia Vs Insulin Glargine U-100 New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba resulted in significantly lower rates of overall, nocturnal and severe hypoglycaemia compared with insulin glargine U-100.[1],[2] Results from the SWITCH 1 and 2 trials, the first completed double-blinded basal insulin studies evaluating the safety profile and efficacy of Tresiba versus insulin glargine U-100,[1],[2] were presented today at the American Diabetes Association 76th Scientific Sessions in In SWITCH 1, patients with type 1 diabetes taking Tresiba compared with insulin glargine U-100 experienced: a rate reduction of 11% in overall symptomatic blood glucose confirmed hypoglycaemic episodes ; a rate reduction of 36% in ... (more)

    Comment?

  12. Successful Switch To Sanofi's Toujeo Evaluated In A Real-World SettingRead the original story

    Sunday Jun 12 | BioSpace

    The U.S. Predictive Health Intelligence Environment database, containing a substantial amount of patient level information, was analyzed to assess Toujeo in this real life setting. The study examined electronic health records to assess the change in HbA1c and occurrence of hypoglycemia in patients up to 6 months after switching to Toujeo from another basal insulin.

    Comment?

  13. Eli Lilly Release: New Data Show Eli Lilly's Once-Weekly Trulicity...Read the original story w/Photo

    Sunday Jun 12 | BioSpace

    Eli Lilly Release: New Data Show Eli Lilly 's Once-Weekly Trulicity In Combination With Insulin Glargine Improves Glycemic Control In People With Type 2 Diabetes /PRNewswire/ -- New data from a completed Phase 3 trial show TrulicityA 1.5 mg significantly reduced hemoglobin A1c and body weight as an add-on to insulin glargine without increasing the risk of low blood sugar after 28 weeks compared to placebo plus insulin glargine. Trulicity is Eli Lilly and Company's once-weekly glucagon-like peptide-1 receptor agonist that is used along with diet and exercise for the treatment of type 2 diabetes.

    Comment?

  14. Sanofi New Diabetes Combo Hits Late-Stage GoalsRead the original story

    Sunday Jun 12 | BioSpace

    Sanofi Announces Positive Phase 3 Results for Investigational Titratable Fixed-Ratio Combination of Insulin Glargine and Lixisenatide - Both pivotal studies demonstrated superior reduction in HbA1c versus insulin glargine and versus lixisenatide - /PRNewswire/ -- Sanofi announced today the presentation of the results of the pivotal Phase 3 LixiLan-O and LixiLan-L clinical trials with the investigational titratable fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide in adults with type 2 diabetes.

    Comment?

  15. New Data Show Lillya s Once-Weekly Trulicity (dulaglutide) in...Read the original story w/Photo

    Sunday Jun 12 | Freshnews

    New data from a completed Phase 3 trial show Trulicity 1.5 mg significantly reduced hemoglobin A1c and body weight as an add-on to insulin glargine without increasing the risk of low blood sugar after 28 weeks compared to placebo plus insulin glargine. Trulicity is Eli Lilly and Company's once-weekly glucagon-like peptide-1 receptor agonist that is used along with diet and exercise for the treatment of type 2 diabetes.

    Comment?

  16. Sanofi Announces Positive Phase 3 Results for Investigational...Read the original story

    Sunday Jun 12 | Freshnews

    Sanofi announced today the presentation of the results of the pivotal Phase 3 LixiLan-O and LixiLan-L clinical trials with the investigational titratable fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide in adults with type 2 diabetes. Both studies met their primary endpoints, demonstrating statistically superior reduction of HbA1c with the titratable fixed-ratio combination versus comparators .

    Comment?

  17. Positive results from pivotal Phase III clinical trials with...Read the original story w/Photo

    Sunday Jun 12 | GlobeNewswire

    Type 2 diabetes patients treated with iGlarLixi had significantly greater reductions in blood glucose versus treatment with either lixisenatide or LantusA The positive Phase III results support Zealand's potential for revenue growth from milestone payments and royalties on iGlarLixi, if approved Regulatory decisions by the U.S. FDA and by the EMA in Europe are expected in August 2016 and in Q1 2017, respectively - Zealand announces that Sanofi today has reported positive results of the pivotal Phase III LixiLan-O and LixiLan-L clinical trials with iGlarLixi , intended for the treatment of type 2diabetes.

    Comment?

  18. Similar efficacy and safety of LY2963016 insulin glargine and insulin ...Read the original story

    Sunday Jun 12 | CiteULike

    Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine in patients with type 2 diabetes who were insulin-naive or previously treated with insulin glargine: a randomized, double-blind controlled trial . To compare the efficacy and safety of LY2963016 insulin glargine and the reference product ) insulin glargine in combination with oral antihyperglycaemic medications in patients with type 2 diabetes .

    Comment?

  19. Eli Lilly and Company logo.Read the original story w/Photo

    Thursday Jun 9 | PR Newswire

    New Data Show Lilly's Once-Weekly TrulicityA in Combination with Insulin Glargine Improves Glycemic Control in People with Type 2 Diabetes /PRNewswire/ -- New data from a completed Phase 3 trial show Trulicity 1.5 mg significantly reduced hemoglobin A1c and body weight as an add-on to insulin glargine without increasing the risk of low blood sugar after 28 weeks compared to placebo plus insulin glargine. Trulicity is Eli Lilly and Company's once-weekly glucagon-like peptide-1 receptor agonist that is used along with diet and exercise for the treatment of type 2 diabetes.

    Comment?

  20. Tresiba (insulin degludec injection U-100) demonstrated significantly ...Read the original story

    Saturday Jun 11 | Freshnews

    New findings from the two phase 3b SWITCH trials showed that treatment with long-acting basal insulin Tresiba resulted in significantly lower rates of overall, nocturnal and severe hypoglycaemia compared with insulin glargine U-100.[1],[2] Results from the SWITCH 1 and 2 trials, the first completed double-blinded basal insulin studies evaluating the safety profile and efficacy of Tresiba versus insulin glargine U-100,[1],[2] were presented today at the American Diabetes Association 76th Scientific Sessions in New Orleans, U.S. In SWITCH 1, patients with type 1 diabetes taking Tresiba compared with insulin glargine U-100 experienced: a rate reduction of 11% in overall symptomatic blood glucose confirmed hypoglycaemic episodes ; a rate reduction of 36% in nocturnal BG confirmed symptomatic hypoglycaemic episodes , and a rate reduction of 35% severe or BG confirmed symptomatic ... (more)

    Comment?